TG Therapeutics, Inc. (TGTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Morrisville, NY, 미국. 현재 CEO는 Michael S. Weiss.
TGTX 을(를) 보유 IPO 날짜 2010-05-03, 352 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $5.52B.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel treatments targeting B-cell malignancies and autoimmune diseases. The company's lead products include Ublituximab, a monoclonal antibody for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis, and Umbralisib, an oral PI3K-delta and CK1-epsilon inhibitor for various lymphomas and leukemia. The pipeline also includes clinical and preclinical candidates such as Cosibelimab (a PD-L1 inhibitor), TG-1701 (a BTK inhibitor), TG-1801 (a bispecific CD47/CD19 antibody), and programs targeting BET, IRAK-4, and GITR. Founded in 1993 and headquartered in New York, TG Therapeutics maintains strategic collaborations and partnerships with leading global pharmaceutical and biotechnology organizations to advance its therapeutic development programs.
